CA2027773A1 - Traitement d'un choc au moyen des cyclodextrines et de leurs derives - Google Patents

Traitement d'un choc au moyen des cyclodextrines et de leurs derives

Info

Publication number
CA2027773A1
CA2027773A1 CA2027773A CA2027773A CA2027773A1 CA 2027773 A1 CA2027773 A1 CA 2027773A1 CA 2027773 A CA2027773 A CA 2027773A CA 2027773 A CA2027773 A CA 2027773A CA 2027773 A1 CA2027773 A1 CA 2027773A1
Authority
CA
Canada
Prior art keywords
shock
treatment
cyclodextrins
derivatives
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2027773A
Other languages
English (en)
Other versions
CA2027773C (fr
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of CA2027773A1 publication Critical patent/CA2027773A1/fr
Application granted granted Critical
Publication of CA2027773C publication Critical patent/CA2027773C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002027773A 1989-10-18 1990-10-16 Traitement d'un choc au moyen des cyclodextrines et de leurs derives Expired - Fee Related CA2027773C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1274425A JPH0672099B2 (ja) 1989-10-18 1989-10-18 抗ショック剤
JP274425/1989 1989-10-18

Publications (2)

Publication Number Publication Date
CA2027773A1 true CA2027773A1 (fr) 1991-04-19
CA2027773C CA2027773C (fr) 2000-03-21

Family

ID=17541495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002027773A Expired - Fee Related CA2027773C (fr) 1989-10-18 1990-10-16 Traitement d'un choc au moyen des cyclodextrines et de leurs derives

Country Status (8)

Country Link
US (1) US5071838A (fr)
EP (1) EP0427402B1 (fr)
JP (1) JPH0672099B2 (fr)
AT (1) ATE90565T1 (fr)
CA (1) CA2027773C (fr)
DE (1) DE69001988T2 (fr)
DK (1) DK0427402T3 (fr)
ES (1) ES2058813T3 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258180A (en) * 1979-11-05 1981-03-24 American Cyanamid Company C6-Modified cyclodextrin sulfate salts as complement inhibitors
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives

Also Published As

Publication number Publication date
EP0427402B1 (fr) 1993-06-16
US5071838A (en) 1991-12-10
DE69001988T2 (de) 1993-09-23
CA2027773C (fr) 2000-03-21
JPH03133931A (ja) 1991-06-07
ES2058813T3 (es) 1994-11-01
EP0427402A2 (fr) 1991-05-15
ATE90565T1 (de) 1993-07-15
DK0427402T3 (da) 1993-08-16
EP0427402A3 (en) 1991-06-12
DE69001988D1 (de) 1993-07-22
JPH0672099B2 (ja) 1994-09-14

Similar Documents

Publication Publication Date Title
AU7404791A (en) Treatment of cataract with 15-keto-prostaglandin compounds
CA2030345A1 (fr) Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques
AU633754B2 (en) Composition for eye drops
GR3015634T3 (en) Process for the preparation of micronised biodegradable particles.
AU5293490A (en) Aryl-substituted rhodanine derivatives
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
ATE202933T1 (de) Immunpotentierende und infektionsschnützende verbindung und ihre herstellung
AU633867B2 (en) Delivery of cytotoxic agents
FI103055B1 (fi) Menetelmä tiomarinolijohdannaisten valmistamiseksi
CA2027773A1 (fr) Traitement d'un choc au moyen des cyclodextrines et de leurs derives
CA2027743A1 (fr) Diurese au moyen des cyclodextrines et de leurs derives
AU1662092A (en) Use of a 1,3-oxathiolan derivative for the treatment of hepatitis b infection
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
AU3406089A (en) Novel strobilurine derivatives, their preparation and their use
AU591419B2 (en) Medicament for curing arteriosclerosis comprising pyrimido (2,1-b) benzothiazole derivative
AU643291B2 (en) Pharmaceutical combination preparations containing cephalosporin and xanthine derivatives and their use
CS318690A3 (en) Pharmaceutical composition usable for depression therapy
DE69016381T2 (de) Behandlung von männlichen, hormonabhängigen Krankheiten mit Cyclodextrinen und Derivaten davon.
FR2631230B1 (fr) Lit pliable, notamment pour application medicale
AU3171393A (en) Use of an animazoline derivative for the treatment of glaucoma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed